StreetAlpha.app
Home › Stocks › ZVRA

Zevra Therapeutics, Inc. (ZVRA)

Healthcare
$8.76
▼ −3.42%
LAST CLOSE · NOV 20

Zevra Therapeutics develops and sells treatments for rare diseases, including MIPLYFFA for Niemann Pick disease type C. It last closed at $8.76 on Nov 20, down 3.42% on the day. The next earnings report for ZVRA is expected around Mon, Mar 8, 2027, after the close. For the quarter ended Sep 2026, ZVRA reported EPS of $0.26 on revenue of $37.8M, with revenue up 44.9% from a year ago. Over its last 8 reports the stock moved an average of 10.0% the session after earnings. Over the last 12 months ZVRA insiders bought $0 of stock on the open market and sold $2.5M, according to SEC Form 4 filings.

AI Auto Pilots
Is ZVRA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ZVRA.

Key Stats

Last 12 months
Results
Revenue
$147.8M
+75.1% vs a year ago
Net income
$78.0M
+120.8% vs a year ago
EPS (diluted)
$1.22
+159.6% vs a year ago
Free cash flow
$38.3M
25.9% margin
Valuation
Market cap
$521.3M
59.5M shares
P/E
7.2
Price over 12 month EPS
Price to sales
3.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$122.1M
At Sep 30
Debt
$0
At Sep 30
Shareholder equity
$238.9M
Shares outstanding
59.5M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $28.6M$28.6MFY2021FY2022: $10.2M$10.2MFY2022FY2023: $27.5M$27.5MFY2023FY2024: $23.6M$23.6MFY2024FY2025: $106.5M$106.5MFY2025

From ZVRA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Mar 8
Estimated date · After the close
Reported EPS
$0.26
Quarter ended Sep 2026
Year ago EPS
-$0.01
Same quarter last year
Revenue
$37.8M
+44.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.69Dec '24Mar 2025: -$0.06Mar '25Jun 2025: $1.21Jun '25Sep 2025: -$0.01Sep '25Dec 2025: $0.19Dec '25Mar 2026: $0.60Mar '26Jun 2026: $0.14Jun '26Sep 2026: $0.26Sep '26Latest $0.26
Revenue by quarter
Dec 2024: $12.0MDec '24Mar 2025: $20.4MMar '25Jun 2025: $25.9MJun '25Sep 2025: $26.1MSep '25Dec 2025: $34.1MDec '25Mar 2026: $36.2MMar '26Jun 2026: $39.7MJun '26Sep 2026: $37.8MSep '26Latest $37.8M
How ZVRA moved after its last 8 reports
Average move the session after a report ±10.0%
Nov 3, 2026After the close+8.9%
Aug 5, 2026After the close+12.8%
May 6, 2026After the close−2.2%
Mar 9, 2026After the close+21.3%
Nov 5, 2025After the close−9.7%
Aug 12, 2025After the close−19.8%
May 13, 2025After the close+3.4%
Mar 11, 2025After the close−1.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ZVRAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ZVRA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ZVRA

Technical Analysis

ZVRA · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 18% below its 20 day and 22% below its 50 day average. It is 24% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot S1 at $8.57, and the nearest resistance the Pivot at $8.89.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.1%/day
Key levels
$15.0452 week high+71.7%
$11.29100 day average+28.9%
$10.85200 day average+23.9%
$10.6850 day average+21.9%
$10.55Swing high (Oct 29)+20.4%
$10.3020 day average+17.6%
$9.07Pivot R1+3.5%
$8.89Pivot+1.5%
$8.76Last close
$8.57Pivot S1−2.2%
$8.0152 week low−8.6%
Indicators
RSI (14)35.54Weak, oversold below 30Neutral
MACD-0.41Below its signal lineBearish
Stochastic5.8Near the bottom of its rangeOversold
ADX (14)23.8Weak trend
Williams %R-98.3Oversold below −80, overbought above −20Oversold
CCI (20)-121.7Oversold below −100, overbought above 100Oversold
Rate of change−24.4%Change over 10 sessionsBearish
ATR (14)$0.62Typical daily range, 7.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ZVRA

What happened before

See how ZVRA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ZVRA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ZVRA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ZVRAHow many large options trades hit ZVRA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ZVRA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲104 buying vs 73 selling
  • ▲Held by funds +1.8 pts
  • ▲Funds holding +16
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding176160+10.0%
In funds' top 1021+100.0%
Held by funds80.2%78.4%+1.8 pts
New / increased41 / 6329 / 66+9.5%
Reduced / sold out48 / 2540 / 17+28.1%
Put/call ratio6.3710.72−40.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ZVRA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ZVRA Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$2.5M13 sales · 6 insiders
95% of the selling was under pre-arranged trading plans.
2026-01 sold $121K2026-02 sold $1.1M2026-05 sold $20K2026-06 sold $438K2026-08 sold $613K2026-10 sold $225KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 12Neil F. McFarlanePresident and CEOSale plan20,000$11.25$225K
Aug 14Rahsaan ThompsonChief Legal & ComplianceSale plan42,666$11.13$475K
Aug 10Corey Michael WattonDirectorSale12,300$11.25$138K
Jun 22Rahsaan ThompsonChief Legal & ComplianceSale plan34,557$12.68$438K
May 11Rahsaan ThompsonChief Legal & ComplianceSale plan1,794$11.30$20K
Feb 9Neil F. McFarlanePresident and CEOSale plan14,625$8.56$125K
Every insider buy and sale for ZVRA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ZVRA insider trades →

From SEC Form 4 filings by ZVRA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZVRA is in one of them and how their past ZVRA trades turned out.

ZVRA in the AI portfolios
Loading…

ZVRA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ZVRA in an article yet. Here's the latest on the wider market.

ZVRA in the news

About Zevra Therapeutics

Zevra Therapeutics develops and sells medicines for rare diseases. Its main approved products are MIPLYFFA, an oral treatment for Niemann Pick disease type C, and OLPRUVA, used to help manage urea cycle disorders in adults and children. The company also has candidates in clinical development, including celiprolol for vascular Ehlers Danlos syndrome. Its products are sold mainly to patients and providers in the United States, and MIPLYFFA is also made available to patients in parts of Europe through an access program. The company is based in Boston, Massachusetts.

Headquarters
Boston, MA